Andrea Knezevic
Overview
Explore the profile of Andrea Knezevic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
1113
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gleeson J, Knezevic A, Bromberg M, Patil S, Sheinfeld J, Carver B, et al.
J Clin Oncol
. 2025 Mar;
:JCO2500475.
PMID: 40085809
No abstract available.
2.
Rosa W, Epstein A, Lauria T, Qualters K, Kapoor-Hintzen N, Knezevic A, et al.
J Pain Symptom Manage
. 2025 Feb;
PMID: 39971213
Context: Patients with advanced cancer discharged from the hospital with no plan for further disease-directed treatment (on 'best supportive care'; BSC) and without specialized palliative care at home are extremely...
3.
Baky F, Matulewicz R, Knezevic A, Hossain J, Williams B, Lee A, et al.
BJU Int
. 2025 Jan;
PMID: 39789892
No abstract available.
4.
Doshi S, Knezevic A, Gonzalez C, Fischer P, Goodman R, Gornell S, et al.
Clin Genitourin Cancer
. 2024 Dec;
23(1):102268.
PMID: 39616970
Purpose: Clinical trials enable renal cell carcinoma (RCC) patients to receive promising investigational agents, yet access may be limited. Telemedicine (TM) is an increasingly utilized platform that can expand access,...
5.
Abramson M, Sathick I, Knezevic A, Perales M, Jaimes E
Kidney360
. 2024 Oct;
PMID: 39446483
Background: Acute kidney injury (AKI) is a common complication of allogeneic hematopoietic cell transplantation (allo-HCT) that increases the risk of mortality. In contrast, higher diversity of intestinal microbiota at the...
6.
Fitzgerald K, Lee C, Voss M, Carlo M, Knezevic A, Peralta L, et al.
Eur Urol
. 2024 Oct;
87(1):96.
PMID: 39426859
No abstract available.
7.
Eismann L, Xie A, Tang C, Knezevic A, Ostrovnaya I, Kuo F, et al.
Eur Urol
. 2024 Oct;
87(1):79-83.
PMID: 39358058
Immunotherapy (ICIs) remains a mainstay for treatment of advanced clear-cell renal cell carcinoma (ccRCC). Biomarker analyses have demonstrated that gene expression profiles are associated with regimen-specific outcomes. These transcriptomic analyses...
8.
Baky F, Liso N, Williams B, Knezevic A, Funt S, Feldman D, et al.
Clin Genitourin Cancer
. 2024 Sep;
22(6):102217.
PMID: 39307609
Background: Patients who undergo primary retroperitoneal lymph node dissection (pRPLND) for early-stage testicular cancer and have no cancer (pN0) found in the retroperitoneum are believed to have an excellent prognosis....
9.
Matulewicz R, Baky F, Knezevic A, Sheinfeld J, Williams B, Kantor R, et al.
Eur Urol Open Sci
. 2024 Sep;
68:1-9.
PMID: 39257620
Background: MicroRNAs (miRNAs) show promise as blood-based tumor markers for germ cell tumors (GCTs), with miRNA-371-3p being the most studied. The marginal benefit of including other candidate miRNAs to aid...
10.
Ma J, Del Balzo L, Walch H, Khaleel S, Knezevic A, Flynn J, et al.
Eur Urol Oncol
. 2024 Aug;
PMID: 39107179
Background: Molecular profiles of renal cell carcinoma (RCC) brain metastases (BMs) are not well characterized. Effective management with locoregional therapies, including stereotactic radiosurgery (SRS), is critical as systemic therapy advancements...